CIRCLES: Effect of Continuous Versus Cyclic Daytime Enteral Nutrition on Circadian Rhythms in Critical Illness

Sponsor
Leiden University Medical Center (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05795881
Collaborator
(none)
60
2
25

Study Details

Study Description

Brief Summary

Disruption of circadian rhythms is frequently observed in patients in the intensive care unit (ICU) and is associated with worse clinical outcomes. The ICU environment presents weak and conflicting timing cues to the circadian clock, including continuous enteral nutrition. The goal of this clinical trial is to evaluate the effect of timing of enteral nutrition on the circadian rhythm in critically ill patients. Patients admitted to the intensive care unit will be allocated to receive either continuous or cyclic daytime (8am to 8 pm) enteral feeding. Differences in circadian rhythms will be assessed by 24h patterns in core body temperature, heart rate variability, melatonin and peripheral clock gene expression. Secondary outcomes include depth of sleep, glucose variability and incidence of feeding intolerance. This study is expected to contribute to the optimalisation of circadian rhythms in the ICU.

Condition or Disease Intervention/Treatment Phase
  • Other: Cyclic daytime enteral nutrition
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
60 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
Investigator-Initiated Randomized Controlled TrialInvestigator-Initiated Randomized Controlled Trial
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Effect of Continuous Versus Cyclic Daytime Enteral Nutrition on Circadian Rhythms in Critical Illness: CIRCLES Study
Anticipated Study Start Date :
Apr 1, 2023
Anticipated Primary Completion Date :
Feb 1, 2025
Anticipated Study Completion Date :
May 1, 2025

Arms and Interventions

Arm Intervention/Treatment
No Intervention: Control group

continuous enteral nutrition: 24 hours a day (standard of care)

Experimental: Intervention group

cyclic daytime enteral nutrition: between 8 a.m. and 8 p.m. (same amount of nutrition as control group)

Other: Cyclic daytime enteral nutrition
The allocated feeding schedule is followed from the start of enteral nutrition after ICU admission until discharge from the ICU.

Outcome Measures

Primary Outcome Measures

  1. Amplitude of 24-h rhythm of core body temperature [Day 3 (8 a.m.) to day 4 (8 a.m.) after start of the study intervention (= start of enteral nutrition)]

    Determined by cosinor analysis

  2. Acrophase 24-h rhythm of core body temperature [Day 3 (8 a.m.) to day 4 (8 a.m.) after start of the study intervention (= start of enteral nutrition)]

    Determined by cosinor analysis

Secondary Outcome Measures

  1. Amplitude of 24-h rhythm of plasma melatonin levels [Day 3 (8 a.m.) to day 4 (8 a.m.) after start of the study intervention (= start of enteral nutrition)]

    Determined by cosinor analysis

  2. Acrophase of 24-h rhythm of plasma melatonin levels [Day 3 (8 a.m.) to day 4 (8 a.m.) after start of the study intervention (= start of enteral nutrition)]

    Determined by cosinor analysis

  3. Amplitude of 24-h rhythm in heart rate variability [Day 3 (8 a.m.) to day 4 (8 a.m.) after start of the study intervention (= start of enteral nutrition)]

    Determined by cosinor analysis

  4. Acrophase of 24-h rhythm in heart rate variability [Day 3 (8 a.m.) to day 4 (8 a.m.) after start of the study intervention (= start of enteral nutrition)]

    Determined by cosinor analysis

  5. Amplitude of 24-h rhythm in systolic blood pressure [Day 3 (8 a.m.) to day 4 (8 a.m.) after start of the study intervention (= start of enteral nutrition)]

    Determined by cosinor analysis

  6. Acrophase of 24-h rhythm in systolic blood pressure [Day 3 (8 a.m.) to day 4 (8 a.m.) after start of the study intervention (= start of enteral nutrition)]

    Determined by cosinor analysis

  7. Amplitude of 24-h rhythm in heart rate [Day 3 (8 a.m.) to day 4 (8 a.m.) after start of the study intervention (= start of enteral nutrition)]

    Determined by cosinor analysis

  8. Acrophase of 24-h rhythm in heart rate [Day 3 (8 a.m.) to day 4 (8 a.m.) after start of the study intervention (= start of enteral nutrition)]

    Determined by cosinor analysis

  9. Peripheral clock gene expression [Day 3 (12 p.m.) to day 4 (12 a.m.) after start of the study intervention (= start of enteral nutrition)]

    Time of day-dependent difference in clock gene expression in PBMCs isolated from blood samples collected at 12 p.m. and 12 a.m.

  10. Depth of sleep [Day 3 (8 a.m.) to day 4 (8 a.m.) after start of the study intervention (= start of enteral nutrition)]

    Daytime (8 a.m. to 8 p.m.) to nighttime (8 p.m. to 8 a.m.) ratio of gamma to delta spectral power ratio in EEG measured with a sleep headband

  11. Mean daily rate of hyperglycaemia/hypoglycaemia [From start of study intervention (enteral nutrition) to end of study intervention]

    Hypoglycaemia is defined as glucose levels < 3.5 mmol/L, hyperglycaemia is defined as glucose levels >10 mmol/L

  12. Mean daily glucose variability [From start of study intervention (enteral nutrition) to end of study intervention]

    Mean of standard deviation of glucose levels per day

  13. Mean daily insulin administration [From start of study intervention (enteral nutrition) to end of study intervention]

    Mean of number of insulin units used per day

  14. Mean daily caloric intake [From start of study intervention (enteral nutrition) to end of study intervention]

    Mean of percentage of recommended calories that patient receives per day of interest during study period

  15. Daily rates of gastric retention [From start of study intervention (enteral nutrition) to end of study intervention]

    Gastric retention is defined as gastric residual volume > 200 mL

  16. 28-day mortality [Up to 28 days]

    28-day mortality

  17. Days on mechanical ventilation [From ICU admission to ICU discharge]

    Days on mechanical ventilation

  18. ICU length of stay [From ICU admission to ICU discharge]

    ICU length of stay

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Age ≥ 18 years old

  • Receiving of or intention to start enteral nutrition via nasogastric or nasoduodenal tube

  • Arterial line

  • Expected duration of ICU admission > 48 hours

Exclusion Criteria:
  • Receiving parenteral nutrition

  • Prior night-time (20.00h - 8.00h) enteral tube feeding within the same hospitalization before study inclusion

  • Readmission to ICU with prior study inclusion

  • Chronic enteral tube feeding prior to current admission

  • Presence of one or more contraindications of enteral feeding and/or at significant risk for gastrointestinal tolerance according to standard protocol (including but not limited to gastrointestinal haemorrhage, intestinal ischemia or necrosis, impaired digestive tract integrity due to obstruction or perforation, gastrectomy, enterectomy, history of gastroparesis or oesophageal dysmotility or expected surgery within 24 hours)

  • Patients with glycaemic emergency (including but not limited to hyperglycaemic hyperosmolar nonketotic coma, diabetic ketoacidosis, severe hypoglycaemia resulting in ICU admission) or patients controlling their glucose levels and insulin dosing via continuous glucose monitoring

  • Expected death within 24 hours

  • Do-not-resuscitate (DNR) order

  • Treatment with extracorporeal membrane oxygenation

  • Severe neurological damage (significant neurological abnormalities such as bleeding, ischemia, neurotrauma or severe encephalopathy with Glasgow Coma Scale ≤ 8)

  • Suspected or confirmed pregnancy

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • Leiden University Medical Center

Investigators

  • Principal Investigator: David J van Westerloo, PhD, MD, Leiden University Medical Center

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
David van westerloo, MD PhD, Leiden University Medical Center
ClinicalTrials.gov Identifier:
NCT05795881
Other Study ID Numbers:
  • P22.080
First Posted:
Apr 3, 2023
Last Update Posted:
Apr 3, 2023
Last Verified:
Mar 1, 2023
Individual Participant Data (IPD) Sharing Statement:
Yes
Plan to Share IPD:
Yes
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by David van westerloo, MD PhD, Leiden University Medical Center
Additional relevant MeSH terms:

Study Results

No Results Posted as of Apr 3, 2023